Clinical, epidemiological and medical device (MD) studies: determination and justification of eligibility at CIR such work becomes complex as we get closer to market launch of a product, even if its development required many years of R&D.
In this respect BOFIP and the new CIR 2024 guide sometimes lack clarity on eligibility clinical studies in human pharmaceuticals and medical devices.
Our 2024 white paper is here to guide you!
Our specialist health sector and taxation of innovation offer you a complete analysis to help you understand where to place the cursor for CIR eligibility of your studies clinical, epidemiological, pharmaco-epidemiological and medical devices.
By downloading this white paper updated with 2024 news, you will discover :
- Conditions governing CIR eligibility for clinical and epidemiological studies according to phase, type and nature
- CIR eligibility criteria for DM studies according to their positioning (before or after CE marking)
- A detailed listing of eligible and non-eligible activities conducted as part of clinical trials
- CIR eligibility for personnel involved in clinical trials
- Of illustrative examples that will help you position
- Analogy with studies conducted in the agri-agro sector (dietary supplements, crop protection products) or industry cosmetics.
Fill in the form below to receive your copy instantly.
Discover our dedicated support for securing your tax credit (CIR, CII, CICo) or your application for JEI status.
Newsletter
Receive all our expert news by e-mail.
Subscribe to our newsletter.
